FDA panel to focus on safety of Novartis gene therapy drugReuters UKIf approved, the drug would be first gene therapy to be approved in the United States. The FDA is not obliged to follow the recommendations of its advisors but typically does so. (Repo… Continue reading
CRISPR Therapeutics and Neon Therapeutics Enter Research CollaborationGlobeNewswire (press release)CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on crea… Continue reading
Genetic Literacy Project |
NY Times’ Carl Zimmer: CRISPR gene editing vital but offers ethical challenges
Genetic Literacy Project [Editor’s Note: Carl Zimmer is a columnist at the New York Times, where his column “Matter” appears each week. He has written books, articles, and essays about the frontiers of biology and how scientists are making efforts to expand our understanding … |
|
Broad Institute of MIT and Harvard Joins Discussions to Create Worldwide CRISPR-Cas9 Licensing Pool
SYS-CON Media (press release) CAMBRIDGE, Mass., July 10, 2017 /PRNewswire/ — Seeking new opportunities to make CRISPR genome editing technology widely available, the Broad Institute of MIT and Harvard has joined discussions to create a non-exclusive CRISPR-Cas9 joint … The Broad Institute of MIT and Harvard Among Those Participating in MPEG LA’s CRISPR-Cas9 Joint Licensing …Digital Journal (press release) |
|
BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
StreetInsider.com The clinical study collaboration between BioLineRx and Genentech, a member of the Roche Group, is part of MORPHEUS, Roche’s Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to assess the efficacy … |